Company Overview

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic central nervous system (CNS) disorders. The company operates within the biotechnology and gene therapy industries, with a primary emphasis on neurological diseases that currently have limited or no approved disease-modifying treatments. Its core business model centers on the research, development, and potential commercialization of gene therapies designed to deliver functional copies of defective genes directly to affected cells in the CNS.

The company’s pipeline has historically included programs targeting disorders such as frontotemporal dementia (FTD) associated with progranulin deficiency, Krabbe disease, and other rare neurodegenerative conditions. Passage Bio was founded in 2017 through a collaboration involving the University of Pennsylvania’s gene therapy research ecosystem, including intellectual property and scientific expertise connected to pioneering AAV research. The company’s strategic positioning has been tied to its access to CNS-focused gene therapy technologies, translational neuroscience capabilities, and relationships with academic research institutions.

Business Operations

Passage Bio primarily operates through a single biotechnology business focused on the discovery and clinical development of investigational genetic medicines. Revenue generation has historically been limited because the company remains in the clinical development stage and has not commercialized approved products. Operations have largely been funded through public equity offerings, strategic financing activities, and collaboration-related arrangements. The company’s primary operational activities include preclinical research, clinical trial execution, regulatory engagement, manufacturing oversight, and intellectual property management.

The company’s therapeutic platform relies heavily on AAV vector technology for CNS-directed gene delivery. Passage Bio has maintained relationships with academic and research institutions connected to the University of Pennsylvania, particularly regarding access to scientific know-how and licensed technologies. Its operations include collaborations with contract development and manufacturing organizations (CDMOs), clinical research organizations, and specialized biotechnology service providers to support vector manufacturing, clinical studies, and regulatory submissions. Data regarding material revenue-generating subsidiaries or large-scale commercial joint ventures remains inconclusive based on available public sources.

Strategic Position & Investments

Passage Bio’s strategic direction has centered on advancing precision genetic medicines for severe neurological disorders with high unmet medical need. The company has prioritized clinical development of programs involving progranulin-associated frontotemporal dementia and other rare CNS diseases where gene replacement or gene expression restoration may offer therapeutic benefit. Its strategy has also included optimizing AAV vector design, improving CNS delivery approaches, and refining biomarker-driven development pathways to support regulatory and clinical progress.

The company has made significant investments in research and development activities, including clinical trial programs and manufacturing capabilities associated with gene therapy production. Passage Bio’s portfolio has historically included investigational candidates such as PBFT02 for progranulin-deficient frontotemporal dementia. The company has also pursued collaborations tied to translational neuroscience and genomic medicine. While Passage Bio has evaluated broader CNS gene therapy opportunities, publicly available information does not confirm major acquisition activity comparable to larger biotechnology consolidators. Data regarding substantial portfolio-company ownership interests or diversified investment holdings is inconclusive based on available public sources.

Geographic Footprint

Passage Bio is headquartered in Philadelphia, Pennsylvania in the United States and conducts operations primarily within the U.S. biotechnology sector. Its research and development activities have been concentrated in North America, particularly through relationships with academic institutions, clinical trial sites, and specialized biotechnology partners focused on CNS disorders and gene therapy development.

The company’s clinical and operational footprint has included collaborations and vendor relationships extending into Europe and other international markets commonly involved in biotechnology manufacturing and clinical research. Although Passage Bio does not operate as a large multinational commercial enterprise, its development programs and regulatory activities have international relevance due to the global nature of rare disease clinical trials, advanced biologics manufacturing, and potential future commercialization pathways.

Leadership & Governance

Passage Bio was founded with scientific and institutional support connected to leaders in gene therapy research at the University of Pennsylvania. The company is governed by a board of directors and executive leadership team with backgrounds in biotechnology, neuroscience, rare diseases, and pharmaceutical development. Corporate strategy has emphasized disciplined capital allocation, advancement of differentiated CNS gene therapy programs, and leveraging translational science to support clinical development.

Key executives have included:

• William “Will” Chou, M.D. – President and Chief Executive Officer
• Patrick Ritschel – Chief Operating Officer and Chief Financial Officer
• Bruce Goldsmith, Ph.D. – Former President and Chief Executive Officer
• Richard Wilson – General Counsel and Corporate Secretary

Leadership communications and public filings have consistently emphasized a strategy focused on rare neurological diseases, clinical execution, regulatory engagement, and the advancement of scalable gene therapy platforms for CNS disorders.